A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

NCT01428297 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Atopic Dermatitis
Netherton Syndrome

Interventions

DRUG: BPR277 ointment (controlled application)
DRUG: Placebo (Vehicle)
DRUG: BPR277 ointment
DRUG: Placebo (Vehicle)
DRUG: BPR277
DRUG: Placebo (Vehicle)

Sponsor

Novartis Pharmaceuticals